Gilead Sciences Statistics

Total Valuation

Gilead Sciences has a market cap or net worth of PEN 557.07 billion. The enterprise value is 602.29 billion.

Market Cap	557.07B
Enterprise Value	602.29B

Important Dates

The next confirmed earnings date is Thursday, May 7, 2026.

Earnings Date	May 7, 2026
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	n/a
Shares Change (QoQ)	-0.08%
Owned by Insiders (%)	0.10%
Owned by Institutions (%)	88.87%
Float	1.24B

Valuation Ratios

The trailing PE ratio is 19.46 and the forward PE ratio is 14.92.

PE Ratio	19.46
Forward PE	14.92
PS Ratio	5.62
PB Ratio	7.32
P/TBV Ratio	n/a
P/FCF Ratio	17.51
P/OCF Ratio	16.53
PEG Ratio	n/a

Enterprise Valuation

The stock's EV/EBITDA ratio is 11.63, with an EV/FCF ratio of 18.93.

EV / Earnings	21.04
EV / Sales	5.82
EV / EBITDA	11.63
EV / EBIT	14.51
EV / FCF	18.93

Financial Position

The company has a current ratio of 1.55, with a Debt / Equity ratio of 1.13.

Current Ratio	1.55
Quick Ratio	1.23
Debt / Equity	1.13
Debt / EBITDA	1.73
Debt / FCF	2.70
Interest Coverage	11.54

Financial Efficiency

Return on equity (ROE) is 40.66% and return on invested capital (ROIC) is 26.86%.

Return on Equity (ROE)	40.66%
Return on Assets (ROA)	12.52%
Return on Invested Capital (ROIC)	26.86%
Return on Capital Employed (ROCE)	25.03%
Weighted Average Cost of Capital (WACC)	n/a
Revenue Per Employee	5.83M
Profits Per Employee	1.68M
Employee Count	17,000
Asset Turnover	0.50
Inventory Turnover	3.58

Taxes

In the past 12 months, Gilead Sciences has paid 4.33 billion in taxes.

Income Tax	4.33B
Effective Tax Rate	13.13%

Stock Price Statistics

The stock price has increased by +12.93% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	+12.93%
50-Day Moving Average	124.62
200-Day Moving Average	115.05
Relative Strength Index (RSI)	100.00
Average Volume (20 Days)	n/a

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	3.45

Income Statement

In the last 12 months, Gilead Sciences had revenue of PEN 99.05 billion and earned 28.63 billion in profits. Earnings per share was 22.81.

Revenue	99.05B
Gross Profit	78.09B
Operating Income	39.75B
Pretax Income	32.96B
Net Income	28.63B
EBITDA	49.04B
EBIT	39.75B
Earnings Per Share (EPS)	22.81

Balance Sheet

The company has 32.34 billion in cash and 85.93 billion in debt, giving a net cash position of -43.58 billion.

Cash & Cash Equivalents	32.34B
Total Debt	85.93B
Net Cash	-43.58B
Net Cash Per Share	n/a
Equity (Book Value)	76.09B
Book Value Per Share	61.54
Working Capital	21.96B

Cash Flow

In the last 12 months, operating cash flow was 33.71 billion and capital expenditures -1.89 billion, giving a free cash flow of 31.81 billion.

Operating Cash Flow	33.71B
Capital Expenditures	-1.89B
Depreciation & Amortization	9.67B
Net Borrowing	-6.27B
Free Cash Flow	31.81B
FCF Per Share	n/a

Margins

Gross margin is 78.84%, with operating and profit margins of 40.14% and 28.90%.

Gross Margin	78.84%
Operating Margin	40.14%
Pretax Margin	33.27%
Profit Margin	28.90%
EBITDA Margin	49.51%
EBIT Margin	40.14%
FCF Margin	32.12%

Dividends & Yields

Gilead Sciences does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	47.04%
Buyback Yield	0.24%
Shareholder Yield	0.24%
Earnings Yield	5.14%
FCF Yield	5.71%

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Gilead Sciences has an Altman Z-Score of 3.9 and a Piotroski F-Score of 7.

Altman Z-Score	3.9
Piotroski F-Score	7